{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:53:48Z","timestamp":1767992028878,"version":"3.49.0"},"reference-count":72,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["IMU-COVID\/Az-1499-21"],"award-info":[{"award-number":["IMU-COVID\/Az-1499-21"]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002745","name":"Bayerische Forschungsstiftung","doi-asserted-by":"publisher","award":["401821119\/GRK2504\/M.M."],"award-info":[{"award-number":["401821119\/GRK2504\/M.M."]}],"id":[{"id":"10.13039\/501100002745","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsche Forschungsgemeinschaft","award":["IMU-COVID\/Az-1499-21"],"award-info":[{"award-number":["IMU-COVID\/Az-1499-21"]}]},{"name":"Deutsche Forschungsgemeinschaft","award":["401821119\/GRK2504\/M.M."],"award-info":[{"award-number":["401821119\/GRK2504\/M.M."]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Starting in 2019, the spread of respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated pandemic of the corona virus disease (COVID-19) has led to enormous efforts in the development of medical countermeasures. Although innovative vaccines have scaled back the number of severe COVID cases, the emergence of the omicron variant (B.1.1.529) illustrates how vaccine development struggles to keep pace with viral evolution. On the other hand, while the recently approved antiviral drugs remdesivir, molnupiravir, and Paxlovid are considered as broadly acting anti-coronavirus therapeutics, only molnupiravir and Paxlovid are orally available and none of these drugs are recommended for prophylactic use. Thus, so far unexploited small molecules, targeting strategies, and antiviral mechanisms are urgently needed to address issues in the current pandemic and in putative future outbreaks of newly emerging variants of concern. Recently, we and others have described the anti-infective potential and particularly the pronounced antiviral activity of artesunate and related compounds of the trioxane\/sesquiterpene class. In particular, the trimeric derivative TF27 demonstrated strong anti-cytomegalovirus activity at nanomolar concentrations in vitro as well as in vivo efficacy after oral administration in therapeutic and even prophylactic treatment settings. Here, we extended this analysis by evaluating TF27 for its anti-SARS-CoV-2 potential. Our main findings are as follows: (i) compound TF27 exerted strong anti-SARS-CoV-2 activity in vitro (EC50 = 0.46 \u00b1 0.20 \u00b5M), (ii) antiviral activity was clearly distinct from the induction of cytotoxicity, (iii) pretreatment with TF27 prevented virus replication in cultured cells, (iv) antiviral activity has likewise been demonstrated in Calu-3 human lung and Caco-2 human colon cells infected with wild-type, delta, or omicron SARS-CoV-2, respectively, and (v) analysis of TF27 combination treatments has revealed synergistic interaction with GC376, but antagonistic interaction with EIDD-1931. Combined, the data demonstrated the pronounced anti-SARS-CoV-2 activity of TF27 and thus highlight the potential of trioxane compounds for further pharmacologic development towards improved options for COVID-specific medication.<\/jats:p>","DOI":"10.3390\/pharmaceutics15010115","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:52:21Z","timestamp":1672282341000},"page":"115","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-8416","authenticated-orcid":false,"given":"Friedrich","family":"Hahn","sequence":"first","affiliation":[{"name":"Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Wangen","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrun","family":"H\u00e4ge","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander University of Erlangen-N\u00fcrnberg, Nikolaus-Fiebiger-Stra\u00dfe 10, 91058 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"},{"name":"Immunic AG, Lochhamer Schlag 21, 82166 Gr\u00e4felfing, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-0951","authenticated-orcid":false,"given":"Svetlana B.","family":"Tsogoeva","sequence":"additional","affiliation":[{"name":"Organic Chemistry Chair I and Interdisciplinary Center for Molecular Materials (ICMM), Friedrich-Alexander University of Erlangen-N\u00fcrnberg, Nikolaus-Fiebiger-Stra\u00dfe 10, 91058 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Marschall","sequence":"additional","affiliation":[{"name":"Institute for Clinical and Molecular Virology, Friedrich-Alexander University of Erlangen-N\u00fcrnberg (FAU), Schlossgarten 4, 91054 Erlangen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e01348-19","DOI":"10.1128\/JVI.01348-19","article-title":"Small-Molecule Antiviral beta-d-N (4)-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance","volume":"93","author":"Agostini","year":"2019","journal-title":"J. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jiab247","article-title":"beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells","volume":"224","author":"Zhou","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.cell.2016.11.010","article-title":"Artemisinins Target GABAA Receptor Signaling and Impair alpha Cell Identity","volume":"168","author":"Li","year":"2017","journal-title":"Cell"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"107706","DOI":"10.1016\/j.pharmthera.2020.107706","article-title":"Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing","volume":"216","author":"Augustin","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00706-021-02759-x","article-title":"Antimalarial and anticancer properties of artesunate and other artemisinins: Current development","volume":"152","author":"Khanal","year":"2021","journal-title":"Monatsh. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/591195","article-title":"The antiviral activities of artemisinin and artesunate","volume":"47","author":"Efferth","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"154259","DOI":"10.1016\/j.phymed.2022.154259","article-title":"Artesunate: A review of its therapeutic insights in respiratory diseases","volume":"104","author":"Zhang","year":"2022","journal-title":"Phytomedicine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.antiviral.2011.07.018","article-title":"The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants","volume":"92","author":"Chou","year":"2011","journal-title":"Antivir. Res"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.antiviral.2005.10.003","article-title":"The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo","volume":"69","author":"Kaptein","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.antiviral.2015.10.003","article-title":"The broad-spectrum antiinfective drug artesunate interferes with the canonical nuclear factor kappa B (NF-kappaB) pathway by targeting RelA\/p65","volume":"124","author":"Hutterer","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jviromet.2011.03.005","article-title":"A reporter system for Epstein-Barr virus (EBV) lytic replication: Anti-EBV activity of the broad anti-herpesviral drug artesunate","volume":"173","author":"Auerochs","year":"2011","journal-title":"J. Virol. Methods"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"104606","DOI":"10.1016\/j.antiviral.2019.104606","article-title":"Artesunate derivative TF27 inhibits replication and pathogenesis of an oncogenic avian alphaherpesvirus","volume":"171","author":"Bertzbach","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1128\/AAC.01800-13","article-title":"Antiviral effects of artesunate on polyomavirus BK replication in primary human kidney cells","volume":"58","author":"Sharma","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1128\/AAC.03714-14","article-title":"Antiviral effects of artesunate on JC polyomavirus replication in COS-7 cells","volume":"58","author":"Sharma","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jcv.2009.05.017","article-title":"Sensitivity of human herpesvirus 6 and other human herpesviruses to the broad-spectrum antiinfective drug artesunate","volume":"46","author":"Milbradt","year":"2009","journal-title":"J. Clin. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ruwizhi, N., Maseko, R.B., and Aderibigbe, B.A. (2022). Recent Advances in the Therapeutic Efficacy of Artesunate. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030504"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Obeid, S., Alen, J., Nguyen, V.H., Pham, V.C., Meuleman, P., Pannecouque, C., Le, T.N., Neyts, J., Dehaen, W., and Paeshuyse, J. (2013). Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0081783"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1002\/chem.201800729","article-title":"Synthesis of Artemisinin-Derived Dimers, Trimers and Dendrimers: Investigation of Their Antimalarial and Antiviral Activities Including Putative Mechanisms of Action","volume":"24","author":"Frohlich","year":"2018","journal-title":"Chemistry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.antiviral.2018.02.013","article-title":"Artesunate-derived monomeric, dimeric and trimeric experimental drugs\u2014Their unique mechanistic basis and pronounced antiherpesviral activity","volume":"152","author":"Hahn","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1016\/j.bmc.2015.07.048","article-title":"Highly potent artemisinin-derived dimers and trimers: Synthesis and evaluation of their antimalarial, antileukemia and antiviral activities","volume":"23","author":"Reiter","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1021\/acsmedchemlett.8b00381","article-title":"Synthesis of Artemisinin-Estrogen Hybrids Highly Active against HCMV, P. falciparum, and Cervical and Breast Cancer","volume":"9","author":"Frohlich","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hahn, F., Hage, S., Herrmann, A., Wangen, C., Kicuntod, J., Jungnickl, D., Tillmanns, J., Muller, R., Fraedrich, K., and Uberla, K. (2021). Methodological Development of a Multi-Readout Assay for the Assessment of Antiviral Drugs against SARS-CoV-2. Pathogens, 10.","DOI":"10.3390\/pathogens10091076"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/acsmedchemlett.7b00412","article-title":"Synthesis of Thymoquinone-Artemisinin Hybrids: New Potent Antileukemia, Antiviral, and Antimalarial Agents","volume":"9","author":"Frohlich","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1016\/j.bmc.2018.05.041","article-title":"Access to new highly potent antileukemia, antiviral and antimalarial agents via hybridization of natural products (homo)egonol, thymoquinone and artemisinin","volume":"26","author":"Reiter","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.bmc.2018.11.018","article-title":"Synthesis of new betulinic acid\/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities","volume":"27","author":"Karagoz","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2018.11.008","article-title":"In vivo proof-of-concept for two experimental antiviral drugs, both directed to cellular targets, using a murine cytomegalovirus model","volume":"161","author":"Sonntag","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"104788","DOI":"10.1016\/j.antiviral.2020.104788","article-title":"The trimeric artesunate derivative TF27 exerts strong anti-cytomegaloviral efficacy: Focus on prophylactic efficacy and oral treatment of immunocompetent mice","volume":"178","author":"Wild","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Hahn, F., Hamilton, S.T., Wangen, C., Wild, M., Kicuntod, J., Bruckner, N., Follett, J.E.L., Herrmann, L., Kheimar, A., and Kaufer, B.B. (2021). Development of a PROTAC-Based Targeting Strategy Provides a Mechanistically Unique Mode of Anti-Cytomegalovirus Activity. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222312858"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Herrmann, A., Jungnickl, D., Cordsmeier, A., Peter, A.S., Uberla, K., and Ensser, A. (2021). Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910188"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/eji.202149374","article-title":"A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model","volume":"52","author":"Peter","year":"2022","journal-title":"Eur. J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","article-title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR","volume":"25","author":"Corman","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nprot.2008.75","article-title":"Neutral red uptake assay for the estimation of cell viability\/cytotoxicity","volume":"3","author":"Repetto","year":"2008","journal-title":"Nat. Protoc."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1021\/acsinfecdis.0c00522","article-title":"Anti-SARS-CoV-2 Potential of Artemisinins In Vitro","volume":"6","author":"Cao","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101873","DOI":"10.1016\/j.tmaid.2020.101873","article-title":"Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation","volume":"37","author":"Gendrot","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"114016","DOI":"10.1016\/j.jep.2021.114016","article-title":"Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants","volume":"274","author":"Nair","year":"2021","journal-title":"J. Ethnopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14571","DOI":"10.1038\/s41598-021-93361-y","article-title":"In vitro efficacy of artemisinin-based treatments against SARS-CoV-2","volume":"11","author":"Zhou","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12985-021-01651-8","article-title":"In vitro efficacy of Artemisia extracts against SARS-CoV-2","volume":"18","author":"Nie","year":"2021","journal-title":"Virol. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"13093","DOI":"10.1038\/s41598-020-70143-6","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","volume":"10","author":"Touret","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"15071","DOI":"10.1038\/ncomms15071","article-title":"Facile access to potent antiviral quinazoline heterocycles with fluorescence properties via merging metal-free domino reactions","volume":"8","author":"Held","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104700","DOI":"10.1016\/j.antiviral.2019.104700","article-title":"A highly potent trimeric derivative of artesunate shows promising treatment profiles in experimental models for congenital HCMV infection in vitro and ex vivo","volume":"175","author":"Jacquet","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Wild, M., Hahn, F., Grau, B., Herrmann, L., Niesar, A., Schutz, M., Lorion, M.M., Ackermann, L., Tsogoeva, S.B., and Marschall, M. (2020). The Artemisinin-Derived Autofluorescent Compound BG95 Exerts Strong Anticytomegaloviral Activity Based on a Mitochondrial Targeting Mechanism. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155578"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"104861","DOI":"10.1016\/j.antiviral.2020.104861","article-title":"Target verification of artesunate-related antiviral drugs: Assessing the role of mitochondrial and regulatory proteins by click chemistry and fluorescence labeling","volume":"180","author":"Hahn","year":"2020","journal-title":"Antivir. Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wild, M., Kicuntod, J., Seyler, L., Wangen, C., Bertzbach, L.D., Conradie, A.M., Kaufer, B.B., Wagner, S., Michel, D., and Eickhoff, J. (2021). Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs). Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020575"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1093\/nar\/19.11.2993","article-title":"Monoclonal antibodies to double-stranded RNA as probes of RNA structure in crude nucleic acid extracts","volume":"19","author":"Oberstrass","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1021\/acs.chemrestox.5b00105","article-title":"Untargeted Proteomics and Systems-Based Mechanistic Investigation of Artesunate in Human Bronchial Epithelial Cells","volume":"28","author":"Ravindra","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1021\/acschembio.5b01043","article-title":"Profiling of Multiple Targets of Artemisinin Activated by Hemin in Cancer Cell Proteome","volume":"11","author":"Zhou","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/S0960-894X(03)00293-2","article-title":"Study on the mechanism of action of artemether against schistosomes: The identification of cysteine adducts of both carbon-centred free radicals derived from artemether","volume":"13","author":"Wu","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1038\/ncomms10111","article-title":"Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum","volume":"6","author":"Wang","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/0006-2952(93)90425-V","article-title":"Alkylation of human albumin by the antimalarial artemisinin","volume":"46","author":"Yang","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12985-022-01802-5","article-title":"Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models","volume":"19","author":"Mautner","year":"2022","journal-title":"Virol. J."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bojkova, D., Reus, P., Panosch, L., Bechtel, M., Rothenburger, T., Kandler, J., Pfeiffer, A., Wagner, J.U.G., Shumliakivska, M., and Dimmeler, S. (2022). Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform. bioRxiv.","DOI":"10.1101\/2022.07.17.500346"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1128\/AAC.00519-12","article-title":"Artemisinin-derived dimer diphenyl phosphate is an irreversible inhibitor of human cytomegalovirus replication","volume":"56","author":"He","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"104639","DOI":"10.1016\/j.antiviral.2019.104639","article-title":"Artemisone demonstrates synergistic antiviral activity in combination with approved and experimental drugs active against human cytomegalovirus","volume":"172","author":"Laskov","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1128\/AAC.00893-13","article-title":"Unique and highly selective anticytomegalovirus activities of artemisinin-derived dimer diphenyl phosphate stem from combination of dimer unit and a diphenyl phosphate moiety","volume":"57","author":"He","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e00288-18","DOI":"10.1128\/AAC.00288-18","article-title":"The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication","volume":"62","author":"Weisblum","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1128\/AAC.01972-13","article-title":"In vitro combination of anti-cytomegalovirus compounds acting through different targets: Role of the slope parameter and insights into mechanisms of Action","volume":"58","author":"Cai","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e01735-18","DOI":"10.1128\/AAC.01735-18","article-title":"Inhibition of Cytomegalovirus Replication with Extended-Half-Life Synthetic Ozonides","volume":"63","author":"Wang","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.joim.2021.07.003","article-title":"An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment","volume":"19","author":"Fuzimoto","year":"2021","journal-title":"J. Integr. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e0333122","DOI":"10.1128\/spectrum.03331-22","article-title":"Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2","volume":"10","author":"Wagoner","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"109133","DOI":"10.1016\/j.celrep.2021.109133","article-title":"Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture","volume":"35","author":"Bafna","year":"2021","journal-title":"Cell Rep."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Gidari, A., Sabbatini, S., Schiaroli, E., Bastianelli, S., Pierucci, S., Busti, C., Comez, L., Libera, V., Macchiarulo, A., and Paciaroni, A. (2022). The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro. Microorganisms, 10.","DOI":"10.20944\/preprints202206.0272.v1"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"De Forni, D., Poddesu, B., Cugia, G., Chafouleas, J., Lisziewicz, J., and Lori, F. (2022). Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0276751"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2105070118","DOI":"10.1073\/pnas.2105070118","article-title":"Deep learning identifies synergistic drug combinations for treating COVID-19","volume":"118","author":"Jin","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jinf.2022.07.023","article-title":"Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants","volume":"85","author":"Bojkova","year":"2022","journal-title":"J. Infect."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Hahn, F., Wangen, C., Hage, S., Peter, A.S., Dobler, G., Hurst, B., Julander, J., Fuchs, J., Ruzsics, Z., and Uberla, K. (2020). IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Viruses, 12.","DOI":"10.3390\/v12121394"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/s41586-022-04482-x","article-title":"Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2","volume":"604","author":"Schultz","year":"2022","journal-title":"Nature"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"104293","DOI":"10.1016\/j.isci.2022.104293","article-title":"Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication","volume":"25","author":"Stegmann","year":"2022","journal-title":"iScience"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41392-022-00956-6","article-title":"A promising strategy against SARS-CoV-2: Pyrimidine inhibitors synergize with nucleoside analogues","volume":"7","author":"Min","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ymthe.2020.12.016","article-title":"Synergistic and Antagonistic Drug Combinations against SARS-CoV-2","volume":"29","author":"Bobrowski","year":"2021","journal-title":"Mol. Ther."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/115\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:55Z","timestamp":1760147695000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["pharmaceutics15010115"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15010115","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}